EMBER-2 study: final results
Prof Patrick Neven, gynaecological oncologist at University Hospital Leuven, summarizes the poster he presented.
A preoperative window-of-opportunity (WOO) study of imlunestrant in ER+, HER- early breast cancer (EBC): Final analysis from EMBER-2.
To administer ER inhibition preoperatively, the pharmacodynamic and safety profiles of Imlunestrant were examined. Among patients with ER-positive, and HER2-negative breast cancer, varying doses of Imlunestrant did not exhibit significant differences in pharmacodynamic biomarkers or tumour histology. The drug demonstrated favourable tolerability, thereby supporting the rationale for additional investigations.
With the educational support of:
 |
 |
 |